Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Abcodia, AIT Austrian Institute of Technology GmbH deal

    Abcodia Ltd., London, U.K. AIT Austrian Institute of Technology GmbH, Vienna, Austria Business: Diagnostic Abcodia partnered with the institute to design a series of longitudinal studies to validate panels of biomarkers…

    Published on 6/17/2013
  • Algeta, Avipep deal

    Algeta ASA (OSE:ALGETA), Oslo, Norway Avipep Pty. Ltd., Parkville, Australia Business: Cancer Algeta and Avipep partnered to develop a targeted thorium conjugate (TTC) combining Algeta's thorium-227, an alpha-particle …

    Published on 6/17/2013
  • Amgen, Cytokinetics deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Business: Cardiovascular Amgen will have exclusive, worldwide rights to develop and commercialize Cytokinetics…

    Published on 6/17/2013
  • Aphios, VivaCell Biotechnology Espana S.L. deal

    Aphios Corp., Woburn, Mass. VivaCell Biotechnology Espana S.L., Cordoba, Spain Business: Neurology The companies partnered to develop and commercialize non-psychotropic cannabinoid drug candidates to treat multiple …

    Published on 6/17/2013
  • AstraZeneca, Cancer Research UK, University of Manchester deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cancer Research UK, London, U.K. University of Manchester, Manchester, U.K. Business: Cancer AstraZeneca and Cancer Research UK's Paterson Institute for Cancer Research …

    Published on 6/17/2013
  • BioLineRx, Jiangsu Chia-Tai Tianqing deal

    BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Jiangsu Chia-Tai Tianqing Pharmaceutical Co. Ltd., Lianyungang, China Business: Infectious BioLineRx granted Jiangsu Chia-Tai exclusive, Chinese rights to …

    Published on 6/17/2013
  • Biolog-id, Institut Curie deal

    Biolog-id, Berney, France Institut Curie, Paris, France Business: Cancer, Other The institute's Curie-Cancer unit partnered with Biolog-id to develop a pilot tracking system of radio frequency identification (RFID) tags…

    Published on 6/17/2013
  • Biological E., Valneva deal

    Biological E. Ltd., Hyderabad, India Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Business: Biomanufacturing Valneva sold its clinical manufacturing operations facility in Nantes, France, to Biological E for an …

    Published on 6/17/2013
  • Bioniche, Paladin deal

    Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Business: Cancer Bioniche granted Paladin exclusive rights to commercialize Urocidin to treat bladder …

    Published on 6/17/2013
  • Conceptus, Bayer deal

    Conceptus Inc. (NASDAQ:CPTS), Mountain View, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Genitourinary Bayer completed its acquisition of Conceptus for $31 per share, or about $1.1 billion (see …

    Published on 6/17/2013
  • Crelux, 4SC, UCB deal

    Crelux GmbH, Martinsried, Germany 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology UCB partnered with Crelux and 4SC's 4SC Discovery GmbH subsidiary to …

    Published on 6/17/2013
  • D.E. Shaw Research LLC, Zealand Pharma deal

    D.E. Shaw Research LLC, New York, N.Y. Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Business: Bioinformatics, Cardiovascular Zealand and D.E. Shaw partnered to use D.E. Shaw's computer-based simulation technology …

    Published on 6/17/2013
  • Elan, Royalty Pharma deal

    Elan Corp. plc (NYSE:ELN), Dublin, Ireland Royalty Pharma, New York, N.Y. Business: Neurology Elan said it is proceeding with a formal sale process "in light of the expressions of interest received to date." Last week, …

    Published on 6/17/2013
  • Flamel deal

    Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France Business: Drug delivery Drug delivery company Flamel partnered with an undisclosed international pharmaceutical partner. Flamel said it expects to receive over $4 …

    Published on 6/17/2013
  • Genomic Vision, Quest Diagnostics deal

    Genomic Vision S.A., Paris, France Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic The partners added two R&D programs to a 2011 deal granting Quest exclusive rights to develop and commercialize …

    Published on 6/17/2013
  • Immune Design, CRI, Ludwig Institute for Cancer Research deal

    Immune Design Corp., Seattle, Wash. Cancer Research Institute, New York, N.Y. Ludwig Institute for Cancer Research, New York, N.Y. Business: Cancer The institutes will conduct clinical trials to evaluate Immune Design's…

    Published on 6/17/2013
  • ImmunoGenes, Corvinus Venture Capital Fund Manager deal

    ImmunoGenes AG, Zug, Switzerland Corvinus Venture Capital Fund Manager, Budapest, Hungary Business: Antibodies ImmunoGenes and Corvinus launched a JV, ImmunoGenes-ABS Zrt. (Godollo, Hungary), to fund the establishment …

    Published on 6/17/2013
  • Isis Pharmaceuticals, Xenon deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Xenon Pharmaceuticals Inc., Burnaby, B.C. Business: Renal Xenon exercised its option under a 2010 deal for an exclusive, worldwide license to XEN701, an …

    Published on 6/17/2013
  • Isomerase Therapeutics Ltd., NeuroVive deal

    Isomerase Therapeutics Ltd., Cambridge, U.K. NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Business: Neurology, Cardiovascular, Infectious NeuroVive partnered with Isomerase to develop and commercialize …

    Published on 6/17/2013
  • Life Technologies, Life Science Korea (LSK) deal

    Life Technologies Corp. (NASDAQ:LIFE), Carlsbad, Calif. Life Science Korea (LSK), Seoul, South Korea Business: Supply/Service Life Technologies acquired South Korean distribution partner LSK. Life Technologies said the …

    Published on 6/17/2013
  • Myriad Genetics, AstraZeneca deal

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pharmacogenetics AstraZeneca will use Myriad's BRACAnalysis test as a companion diagnostic to select …

    Published on 6/17/2013
  • NeuroVive, Sihuan deal

    NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460), Haikou, China Business: Cardiovascular, Neurology NeuroVive said its NeuroVive Pharmaceutical Asia Ltd. …

    Published on 6/17/2013
  • Oculus deal

    Oculus Innovative Sciences Inc. (NASDAQ:OCLS), Petaluma, Calif. Business: Infectious Oculus granted its Ruthigen Inc. biotech subsidiary an exclusive license to develop and commercialize Oculus' RUT58-60 for invasive …

    Published on 6/17/2013
  • Pearl Therapeutics, AstraZeneca deal

    Pearl Therapeutics Inc., Redwood City, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pulmonary, Inflammation AstraZeneca will acquire Pearl for $560 million up front. Pearl will be eligible for up …

    Published on 6/17/2013
  • RepliCel, Shiseido Co. Ltd. deal

    RepliCel Life Sciences Inc. (OTCBB:REPCF), Vancouver, B.C. Shiseido Co. Ltd. (Tokyo:4911; Pink:SSDOY), Tokyo, Japan Business: Dermatology RepliCel granted skincare company Shiseido exclusive rights to RCH-01 hair …

    Published on 6/17/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993